U.S. MRI Guided Neurosurgical Ablation Market Set to Boom to US$ 92.2 Million by 2032, Says PMR

U.S. MRI-Guided Neurosurgical Ablation Market: 2025-2032 Outlook

The U.S. MRI guided neurosurgical ablation market is likely to value at US$ 62.1 Mn in 2025 and reach US$ 92.2 Mn by 2032, growing at a CAGR of 5.8 % during the forecast period from 2025 to 2032.

Download Sample PDF Of This Report: https://www.persistencemarketresearch.com/samples/35661

In recent years, the neurosurgical field has witnessed a paradigm shift toward minimally invasive interventions aided by real-time imaging. MRI-guided neurosurgical ablation-using techniques such as laser interstitial thermal therapy (LITT) or MRI-guided focused ultrasound (MRgFUS)-offers the ability to target difficult-to-access brain lesions, seizure foci, or movement disorder loci with high precision and minimal collateral damage. As adoption grows, the U.S. market is poised for steady expansion, driven by growing disease burden, technology enhancements, shifting reimbursement landscapes, and institutional investments.

Below, we delve into market drivers, restraints, segment dynamics, competitive landscape, and future prospects.

For More Information:
https://www.persistencemarketresearch.com/market-research/us-mri-guided-neurosurgical-ablation-market.asp

Market Drivers & Growth Enablers

Rising Burden of Brain Tumors, Epilepsy & Movement Disorders

In the U.S., the incidence of primary brain and central nervous system tumors (malignant and non-malignant) is approximately 25.34 per 100,000 population (2020-2024).

Meanwhile, epilepsy affects around 1.1 % of U.S. adults (~2.9 million people), many of whom have drug-refractory disease.

Many of these disease states involve lesions in deep, eloquent or hard-to-reach brain areas, making conventional open surgery risk-laden. MRI-guided ablation methods allow precise, image-guided destruction of pathological tissue while sparing critical surroundings-thus appealing in neurosurgical management.

Preference for Minimally Invasive & Real-Time MRI Precision
Clinicians and patients increasingly prefer less invasive neurosurgical approaches that reduce recovery time, complications, and hospital stay. The ability to monitor ablation in real time under MRI guidance (temperature maps, feedback) enhances safety and efficacy, making such procedures more attractive.

Regulatory Approvals & Reimbursement Expansion

FDA clearance for systems like VisualaseTM supports clinical adoption across indications such as brain tumors, epileptic foci, and radiation necrosis.
Persistence Market Research

Insurance coverage changes are improving access: for example, in 2021, Health Care Service Corporation (HCSC) began covering LITT for ~16 million members; Medicare has extended coverage for MRgFUS for essential tremor in many states.

As payors become more comfortable with MRI-guided ablation as a standard of care, this removes a key barrier to adoption and encourages hospitals to invest.

Technological Innovation & AI Integration
Advancements in compact MRI-compatible systems, AI-assisted treatment planning, and portable guidance architectures are making systems more efficient, cost-effective, and adaptable to varied neurosurgical settings. These innovations help expand reach beyond top-tier academic centers.

Institutional Infrastructure & Neurosurgical Capacity
Large hospitals and major neurosurgical centers already maintain MRI suites and expert teams. Their readiness to integrate ablation systems offers a natural staging ground for incremental uptake. As success stories and clinical evidence accumulate, diffusion to other hospitals becomes more feasible.

Market Restraints & Challenges

High Capital & Operating Costs
Building or retrofitting MRI suites is capital-intensive. A high-field MRI scanner can cost between US$ 1-3 million (excluding shielding, cooling, facility modifications).
Persistence Market Research

The per-procedure costs of LITT (consumables, hospitalization, imaging, physician fees) can reach a median of ~US$ 21,800 (ranges $11,000-$32,800).
Persistence Market Research

Such steep costs limit adoption to well-funded centers and constrain broader diffusion into smaller community hospitals or rural locations.

Reimbursement Complexity & Coverage Gaps
Although insurance policies are evolving, reimbursement coverage is not universal or uniform across states and payors. Delays or denials in coverage create uncertainty that can slow adoption. Some newer or off-label applications may lack established reimbursement pathways.

Clinical Evidence Gaps & Long-Term Data
While clinical outcomes for MRI-guided ablation are promising, long-term comparative data (versus open surgery or radiosurgery) are still emerging. Skepticism or cautious adoption may persist until large-scale outcomes, survival, and cost-effectiveness evidence solidifies.

Operational & Training Barrier
Deployment of MRI-guided ablation requires coordination among neurosurgeons, radiologists, MRI technologists, and anesthesiologists. Training, workflow integration, safety protocols, and maintenance demand institutional investment in human capital.

Segmental Insights & Trends
By Product Type

MRI-guided laser therapy systems are projected to dominate in 2025 (≈ 45.6 % market share). This is supported by historical clinical validation, FDA clearances, and established neurosurgical center installations.
Persistence Market Research

MRI-guided focused ultrasound (MRgFUS) systems are expected to be the fastest-growing segment. Their noninvasive nature, favorable safety profile, and expanding regulatory approvals (e.g., for movement disorders) are fueling growth momentum.

By Indication

Brain Tumors: Given the incidence and clinical complexity of intracranial tumors, this remains a leading indication for MRI-guided ablation. Conventional surgical resection often carries high risk to adjacent structures; ablation offers a safer alternative in selected cases.

Epilepsy: MRI-guided laser ablation is increasingly used in medically refractory epilepsy cases targeting discrete foci, especially in deep or eloquent brain regions.

Movement Disorders / Radiation Necrosis / Other: Over time, the use of MRI-guided ablation may expand into tremor control, Parkinson's disease targets, and treatment of radiation necrosis lesions (recurrent tumor vs. necrosis).

By End User

Hospitals lead adoption, accounting for ~50.1 % of the market in 2025. Their existing MRI infrastructure, neurosurgical expertise, and high patient throughput make them ideal adopters.

Ambulatory Surgical Centers (ASCs) and Research Institutions are smaller but increasingly relevant channels, particularly as compact, lower-cost systems emerge and research applications expand.

Competitive Landscape & Strategic Moves

Key players active in the U.S. MRI-guided neurosurgical ablation market include:

Medtronic plc
Insightec
Monteris Medical
Philips Healthcare
GE Healthcare
Siemens Healthineers
Profound Medica
ClearPoint Neuro, Inc.
Elekta AB

Boston Scientific Corporation

These incumbents focus on improving system precision, real-time MRI guidance, seamless integration into neurosurgical workflows, and safety enhancements. In parallel, emerging competitors emphasize affordability, compact designs, AI-driven planning, and modular add-ons tailored for niche neurosurgical settings.

Recent industry developments:

In July 2025, Insightec received FDA approval for staged bilateral focused ultrasound therapy in Parkinson's disease-allowing MRgFUS ablation on both hemispheres in a staged protocol.
Persistence Market Research

In June 2025, Medtronic obtained FDA 510(k) clearance for its next-generation VisualaseTM V2 MRI-Guided Laser Ablation System, offering enhancements in real-time guidance and procedural safety.

Other profitability-enabling initiatives include developing more favorable reimbursement codes, incremental system upgrades (e.g., improved thermometry, tracking), and partnerships with neuro-imaging and AI software firms to boost clinical decision support.

Market Forecast & Growth Outlook

At a baseline of US$ 62.1 Mn in 2025, the U.S. MRI-guided neurosurgical ablation market is forecast to expand to US$ 92.2 Mn by 2032, reflecting a CAGR of 5.8 % over the period.
Persistence Market Research

This moderate-to-strong growth trajectory reflects both the increasing uptake of these advanced therapies and the gradual overcoming of adoption barriers. Some specific projections and expectations include:

Product mix shift: Over time, the share of MRgFUS is expected to rise faster than laser systems, gradually narrowing the dominance gap.

Expansion into new indications: As safety and data improve, newer use cases (such as movement disorder ablation, pediatric epilepsy, or deep-seated tumor ablation) may garner increased share.

Widening geographic and institutional reach: Beyond flagship neurosurgical centers, mid-tier hospitals and tertiary care systems may begin implementing MRI ablation suites, spurred by analog improvements in system cost, integration, and reimbursement assurance.

Pricing & value optimization: As procedural volumes rise and competition intensifies, suppliers may optimize pricing or introduce subscription, leasing, or modular models to accelerate adoption.

Ecosystem play: Coupling ablation systems with AI planning suites, imaging analytics, and integrated neuro-navigation may create bundled offerings that further differentiate vendors.

Despite challenges, the upward trajectory is underpinned by solid fundamentals-technological maturity, clinical demand, and improving market readiness.

Key Takeaways & Strategic Implications

The U.S. MRI-guided neurosurgical ablation market is on a growth path, expanding from ~US$ 62 Mn (2025) to ~US$ 92 Mn (2032) at ~5.8 % CAGR.

Laser-based systems will maintain leadership in the near term, but focused ultrasound systems are likely to outpace growth rates due to their noninvasive nature.

Major growth levers include rising prevalence of CNS disease, rising preference for minimally invasive neurosurgery, broader insurance coverage, and AI-driven innovation.

Key constraints revolve around high upfront and per-procedure costs, reimbursement uncertainties, logistical and clinical training barriers, and evolving evidence base.

Market participants must focus on strategies such as flexible financing (leasing, subscriptions), modular systems, AI-enabled planning tools, and strong clinical evidence generation to differentiate and accelerate adoption.

Read More Related Reports:

Reprocessed Single-Use Devices Market - https://www.persistencemarketresearch.com/market-research/reprocessed-single-use-devices-market.asp

Hip Resurfacing Implants Market -
https://www.persistencemarketresearch.com/market-research/hip-resurfacing-implants-market.asp

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.